Viewing Study NCT04847102

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:46 AM
Ignite Modification Date: 2026-05-20 @ 1:12 AM
Study NCT ID: NCT04847102
Status: UNKNOWN
Last Update Posted: 2021-11-18
First Post: 2021-04-13
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above
Sponsor: Walvax Biotechnology Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None COVID-19 View
None SARS-CoV-2 View
Keywords:

Keywords

Keyword Brief Keyword Text View
None SARS-CoV-2 mRNA vaccine View
None Efficacy View
None Safety View
None Immunogenicity View